COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients.
WHO is extremely concerned that -- as occurred with COVID-19 vaccines -- low- and middle-income countries will again be pushed to the end of the queue when it comes to accessing this treatment.
Pfizer has, and continues to, strike deals to sell the treatment in a number of countries, but details around pricing remain largely confidential.
The originator product, sold under the name Paxlovid, will be included in the WHO prequalification list, but generic products are not yet available from quality-assured sources according to WHO.